RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > It’s The Law: FDA Issues Draft Guidance on Financial Disclosure by Clinical Investigators

It’s The Law: FDA Issues Draft Guidance on Financial Disclosure by Clinical Investigators

Posted 01 July 2011 | By Katherine R. Leibowitz 

On 24 May 2011, the US Food and Drug Administration (FDA) released draft guidance to replace its current guidance on disclosure of financial interests held by clinical investigators.1 The draft guidance reflects the changing landscape both within and outside FDA regarding transparency of financial interests. Consistent with increased public attention to physician-industry financial ties, the tenor of the draft guidance suggests that clinical trial sponsors should expect a more rigorous review by FDA of these financial arrangements. Comments on the draft guidance must be submitted by 25 July 2011.


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.